Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.39 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172375 | 0.92 | FAAH (0.36) | AURKAAURKBINCENPFAAHCNR2 | |
| SCHEMBL400349 | 0.92 | FAAH (0.36) | AURKAAURKBINCENPFAAHCNR2 | |
| SCHEMBL14776056 | 0.92 | AURKA (0.38) | AURKAAURKBINCENP | |
| SCHEMBL3529102 | 0.91 | AURKA (0.37) | AURKAAURKBINCENPFAAHCNR2 | |
| SCHEMBL3526082 | 0.89 | AURKA (0.40) | AURKAAURKBFAAH | |
| SCHEMBL3529733 | 0.89 | AURKA (0.40) | AURKAAURKBFAAH | |
| Trifluoroacetic Acid SCHEMBL397827 | 0.89 | AURKA (0.34) | AURKAAURKBINCENPFAAHCNR2 | |
| Trifluoroacetic Acid SCHEMBL15225961 | 0.89 | AURKA (0.34) | AURKAAURKBINCENPFAAHCNR2 | |
| SCHEMBL10172360 | 0.83 | AURKA (0.38) | AURKAAURKBINCENPFAAHEGFR | |
| SCHEMBL400511 | 0.83 | AURKA (0.38) | AURKAAURKBINCENPFAAHEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | claimed |
| EP-1828165-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-03-20 | — | — | EP | claimed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | claimed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | claimed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | claimed |
| EP-1813609-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | MSD KK (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1828165-B1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD KK (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-7834018-B2 | aurora kinase inhibitors; 2-(thiazol-2-ylamino)pyridine compounds as antitumor agents; 6-((4-(3-chloro-2-fluorobenzoyl)piperazin-1-yl)methyl)-N-thiazol-2-ylpyridin-2-amine for example | BANYU PHARMACEUTICAL CO., LTD (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7491720-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | OHKUBO MITSURU | 2008-01-31 | — | — | US | disclosed |
| EP-1813609-A2 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027042-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885INCENP 506/4885 |
| US-20060106029-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885INCENP 506/4885 |
| US-20090149470-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885INCENP 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.